The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations

被引:3
|
作者
Wumener, Xieraili [1 ,2 ]
Zhang, Yarong [1 ,2 ]
Zang, Zihan [3 ]
Du, Fen [1 ,2 ]
Ye, Xiaoxing [2 ,4 ]
Zhang, Maoqun [1 ,2 ]
Liu, Ming [1 ,2 ]
Zhao, Jiuhui [1 ,2 ]
Sun, Tao [5 ]
Liang, Ying [1 ,2 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Shenzhen Clin Res Ctr Canc, Dept Nucl Med,Natl Canc Ctr,Natl Clin Res Ctr Canc, Shenzhen, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen Clin Res Ctr Canc, Shenzhen, Peoples R China
[3] Shenzhen Middle Sch, Shenzhen, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Clin Res Ctr Canc, Dept Pathol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Shenzhen, Peoples R China
[5] Chinese Acad Sci, Shenzhen Inst Adv Technol, Paul C Lauterbur Res Ctr Biomed Imaging, Shenzhen, Peoples R China
来源
BMC PULMONARY MEDICINE | 2024年 / 24卷 / 01期
关键词
Dynamic imaging; PET/CT; F-18-FDG; Non-small cell lung cancer; Epidermal growth factor receptor; SOLITARY PULMONARY NODULES; OPEN-LABEL; BENIGN; TUMOR; TOMOGRAPHY; GEFITINIB; ACCURACY; ARTIFACT; 1ST-LINE; REGION;
D O I
10.1186/s12890-024-02997-9
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Objectives F-18-fluorodeoxyglucose (FDG) PET/CT has been widely used for the differential diagnosis of cancer. Semi-quantitative standardized uptake value (SUV) is known to be affected by multiple factors and may make it difficult to differentiate between benign and malignant lesions. It is crucial to find reliable quantitative metabolic parameters to further support the diagnosis. This study aims to evaluate the value of the quantitative metabolic parameters derived from dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting epidermal growth factor receptor (EGFR) mutation status. Methods We included 147 patients with lung lesions to perform FDG PET/CT dynamic plus static imaging with informed consent. Based on the results of the postoperative pathology, the patients were divided into benign/malignant groups, adenocarcinoma (AC)/squamous carcinoma (SCC) groups, and EGFR-positive (EGFR+)/EGFR-negative (EGFR-) groups. Quantitative parameters including K-1, k(2), k(3), and K-i of each lesion were obtained by applying the irreversible two-tissue compartmental modeling using an in-house Matlab software. The SUV analysis was performed based on conventional static scan data. Differences in each metabolic parameter among the group were analyzed. Wilcoxon rank-sum test, independent-samples T-test, and receiver-operating characteristic (ROC) analysis were performed to compare the diagnostic effects among the differentiated groups. P < 0.05 were considered statistically significant for all statistical tests. Results In the malignant group (N = 124), the SUVmax, k(2), k(3), and K-i were higher than the benign group (N = 23), and all had-better performance in the differential diagnosis (P < 0.05, respectively). In the AC group (N = 88), the SUVmax, k(3), and K-i were lower than in the SCC group, and such differences were statistically significant (P < 0.05, respectively). For ROC analysis, K-i with cut-off value of 0.0250 ml/g/min has better diagnostic specificity than SUVmax (AUC = 0.999 vs. 0.70). In AC group, 48 patients further underwent EGFR testing. In the EGFR (+) group (N = 31), the average K-i (0.0279 +/- 0.0153 ml/g/min) was lower than EGFR (-) group (N = 17, 0.0405 +/- 0.0199 ml/g/min), and the difference was significant (P < 0.05). However, SUVmax and k(3) did not show such a difference between EGFR (+) and EGFR (-) groups (P>0.05, respectively). For ROC analysis, the K-i had a cut-off value of 0.0350 ml/g/min when predicting EGFR status, with a sensitivity of 0.710, a specificity of 0.588, and an AUC of 0.674 [0.523-0.802]. Conclusion Although both techniques were specific, Ki had a greater specificity than SUVmax when the cut-off value was set at 0.0250 ml/g/min for the differential diagnosis of lung cancer. At a cut-off value of 0.0350 ml/g/min, there was a 0.710 sensitivity for EGFR status prediction. If EGFR testing is not available for a patient, dynamic imaging could be a valuable non-invasive screening method.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations
    Wumener, Xieraili
    Sun, Tao
    Liang, Ying
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [2] Correlation between F-18 FDG PET/CT and EGFR mutations in lung adenocarcinoma
    Park, Sonya Youngju
    Yoo, Ie Ryung
    Park, Hye Lim
    Choi, Woo Hee
    Han, Eun Ji
    Kim, Sung Hoon
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [3] The value of net influx constant based on FDG PET/CT dynamic imaging in the differential diagnosis of metastatic from non-metastatic lymph nodes in lung cancer
    Wumener, Xieraili
    Zhao, Jun
    Liang, Ying
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [4] The value of net influx constant based on FDG PET/CT dynamic imaging in the differential diagnosis of metastatic from non-metastatic lymph nodes in lung cancer
    Wumener, Xieraili
    Zhang, Yarong
    Zang, Zihan
    Ye, Xiaoxing
    Zhao, Jiuhui
    Zhao, Jun
    Liang, Ying
    ANNALS OF NUCLEAR MEDICINE, 2024, 38 (11) : 904 - 912
  • [5] Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma
    Han, Xiaoyu
    Fan, Jun
    Li, Yumin
    Cao, Yukun
    Gu, Jin
    Jia, Xi
    Wang, Yuhui
    Shi, Heshui
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [6] Value of CT features for predicting EGFR mutations and ALK positivity in patients with lung adenocarcinoma
    Xiaoyu Han
    Jun Fan
    Yumin Li
    Yukun Cao
    Jin Gu
    Xi Jia
    Yuhui Wang
    Heshui Shi
    Scientific Reports, 11
  • [7] Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
    Ahmet Bilici
    Bala Basak Oven Ustaalioglu
    Mesut Seker
    Nesrin Canpolat
    Bulent Tekinsoy
    Taflan Salepci
    Mahmut Gumus
    European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 : 1259 - 1269
  • [8] Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
    Bilici, Ahmet
    Ustaalioglu, Bala Basak Oven
    Seker, Mesut
    Canpolat, Nesrin
    Tekinsoy, Bulent
    Salepci, Taflan
    Gumus, Mahmut
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (07) : 1259 - 1269
  • [9] Predictive Value of Initial 18F-FDG PET/CT for Identifying EGFR and KRAS Mutations in Patients with Non-small-cell Lung Cancer
    Topuz, Ozge Vural
    Buyukpinarbasili, Nur
    HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, 2024, 62 (05): : 255 - 264
  • [10] Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer
    Shi, Aiqi
    Wang, Jianling
    Wang, Yuzhu
    Guo, Guorong
    Fan, Chouchou
    Liu, Jiangyan
    ANNALS OF NUCLEAR MEDICINE, 2022, 36 (04) : 393 - 400